Abbott Laboratories
NYSE:ABT
$ 110.56
$-0.77 (-0.64%)
$ 110.56
$-0.77 (-0.64%)
Real-time: 03/22/2024 15:59

Abbott Laboratories Stock

About Abbott Laboratories

Abbott Laboratories (Abbott) engages in the discovery, development, manufacture, and sale of a broad and diversified line of health care products. Abbott Laboratories share price history

Segments

Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

Established Pharmaceutical Products

This segment’s products include a broad line of branded generic pharmaceuticals manufactured worldwide and marketed and sold outside the United States in emerging markets. These products are generally sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers or public warehouses, depending on the market served. Certain products are co-marketed or co-promoted with, or licensed from, other companies.

The principal products included in the broad therapeutic area portfolios of the Established Pharmaceutical Products segment are: Abbott Laboratories share price history

Gastroenterology products, including Creon, for the treatment of pancreatic exocrine insufficiency associated with several underlying conditions, including cystic fibrosis and chronic pancreatitis; Duspatal and Dicetel, for the treatment of irritable bowel syndrome or biliary spasm; Heptral, Transmetil, and Samyr, for the treatment of intrahepatic cholestasis (associated with liver disease) or depressive symptoms; and Duphalac, for regulation of the physiological rhythm of the colon;

Women’s health products, including Duphaston, for the treatment of many different gynecological disorders; and Femoston, a hormone replacement therapy for postmenopausal women;

Cardiovascular and metabolic products, including Lipanthyl and TriCor, for the treatment of dyslipidemia; Teveten and Teveten Plus, for the treatment of essential hypertension, and Physiotens, for the treatment of hypertension; and Synthroid, for the treatment of hypothyroidism;

Pain and central nervous system products, including Serc, for the treatment of Menière’s disease and vestibular vertigo; Brufen, for the treatment of pain, fever, and inflammation; and Sevedol, for the treatment of severe migraines; and

Respiratory drugs and vaccines, including the anti-infective clarithromycin (sold under the trademarks Klacid, Claribid, and Klaricid); and Influvac, an influenza vaccine.

The Established Pharmaceutical Products segment directs its primary marketing efforts toward building strong brands with key stakeholders, including consumers, pharmacists, physicians, and other healthcare providers. Government agencies are also important customers.

Diagnostic Products

This segment’s products include a broad line of diagnostic systems and tests manufactured, marketed, and sold worldwide. These products are generally marketed and sold directly to blood banks, hospitals, commercial laboratories, clinics, physicians’ offices, retailers, government agencies, alternate care testing sites, and plasma protein therapeutic companies from Abbott-owned distribution centers, public warehouses or third party distributors.

The principal products included in the Diagnostic Products segment are:

Core laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing, including the Alinity family of instruments along with the ARCHITECT and Cell-Dyn systems. These systems are used for screening and/or diagnosis for cancer, cardiac and metabolic disorders, drugs of abuse, thyroid function, fertility, neurologic and general chemistries, infectious diseases, such as hepatitis and HIV, therapeutic drug monitoring, and a suite of SARS-CoV-2 serology assays.

Molecular diagnostics polymerase chain reaction (PCR) instrument systems, including Alinity m and m2000 that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents, including HIV, hepatitis, HPV, sexually transmitted infections, SARS-CoV-2 and influenza A & B, and respiratory syncytial virus (RSV); and products for oncology with the Vysis FISH product line of genomic-based tests.

Point-of-care systems, including the i-STAT and i-STAT Alinity and cartridges for testing blood gas, chemistry, electrolytes, coagulation and immunoassay.

Rapid diagnostics lateral flow testing products in the area of infectious diseases, such as SARS-CoV-2, including the BinaxNOW and Panbio rapid testing platforms, influenza, HIV, hepatitis, and tropical diseases, such as malaria and dengue fever; molecular point-of-care testing for HIV, including the m-PIMA HIV-1/2 Viral Load Test, and for SARS-CoV-2 and influenza A & B, RSV and strep A, including the ID NOW rapid molecular system; cardiometabolic testing, including Afinion and Cholestech LDX platforms and tests; and a toxicology business for drug and alcohol testing.

Informatics and automation solutions for use in laboratories, including laboratory automation systems, such as the GLP systems track, the RALS point-of-care solution, and AlinIQ, a suite of informatics tools and professional services.

Nutritional Products

This segment’s products include a broad line of pediatric and adult nutritional products manufactured, marketed, and sold worldwide. These products are generally marketed and sold directly to consumers and to institutions, wholesalers, retailers, health care facilities, government agencies, and third-party distributors from Abbott-owned distribution centers or third-party distributors.

The principal products included in the Nutritional Products segment are:

Various forms of infant formula and follow-on formula, including Similac, Similac 360 Total Care, Similac Pro-Advance, Similac Advance, Similac 360 Total Care Sensitive, Similac Sensitive, Go & Grow by Similac, Similac NeoSure, Similac Organic, Similac Special Care, Similac Total Comfort, Similac Soy Isomil, Similac Alimentum, EleCare, Gain, and Grow.

Adult and other pediatric nutritional products, including Ensure, Ensure Plus, Ensure Enlive, Ensure (with NutriVigor), Ensure Max Protein, Ensure High Protein, Glucerna, Glucerna Hunger Smart, ProSure, PediaSure, PediaSure SideKicks, PediaSure Peptide, Juven, Abound, Pedialyte and Zone Perfect.

Nutritional products used in enteral feeding in health care institutions, including Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite, Oxepa, Freego (Enteral Pump) and Freego sets, Nepro, and Vital.

Primary marketing efforts for nutritional products are directed toward consumers or to securing the recommendation of Abbott’s brand of products by physicians or other health care professionals. In addition, nutritional products are promoted directly to the public by consumer marketing efforts in markets where permitted.

Medical Devices

This segment’s products include a broad line of rhythm management, electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. Medical devices are manufactured, marketed and sold worldwide. In the United States, depending upon the product, medical devices are generally marketed and sold directly to wholesalers, hospitals, ambulatory surgery centers, physicians’ offices, and distributors from Abbott-owned distribution centers, public warehouses or third party distributors. Outside the United States, sales are made either directly to customers or through distributors, depending on the market served.

The principal products included in the Medical Devices segment are:

Rhythm management products, including Assurity MRI and Endurity MRI pacemaker systems, and Aveir single-chamber (VR and AR) and Aveir dual chamber (DR) leadless pacemaker systems; Ellipse, Fortify Assura, and Gallant implantable cardioverter defibrillators and Gallant and Quadra Assura MP implantable cardioverter defibrillator with cardiac resynchronization therapy and MultiPoint Pacing technology; and Confirm Rx, Jot Dx and Assert-IQ implantable cardiac monitors.

Electrophysiology products, including the TactiFlex and TactiCath families of ablation catheters, and FlexAbility irrigated ablation catheters; EnSite family of cardiac mapping systems; Agilis NxT and Swartz introducer catheters; the Advisor HD Grid mapping catheter; and ViewFlex family of intracardiac echocardiography catheters.

Heart failure related products, including the HeartMate left ventricular assist device family; the CardioMEMS HF System pulmonary artery sensor, a heart failure monitoring system; the CentriMag System, an acute mechanical circulatory support system; and patient self-testing products and services.

Vascular products, including the XIENCE family of drug-eluting coronary stent systems developed on the Multi-Link Vision platform; StarClose SE, Perclose ProGlide and Perclose ProStyle vessel closure devices, TREK coronary balloon dilatation products, Hi-Torque Balance Middleweight Universal II guidewires, Supera Peripheral Stent System, a peripheral vascular stent system; Acculink/Accunet and Xact/Emboshield NAV6, carotid stent systems; the OPTIS integrated systems with Ultreon 1.0 and 2.0 Software, compatible with the Dragonfly OPTIS and OpStar imaging catheters and PressureWire fractional flow reserve measurement systems; the JETi peripheral thrombectomy systems for clot removal; and Diamondback 360 coronary and peripheral orbital atherectomy systems.

Structural heart products, including MitraClip, a mitral valve transcatheter edge-to-edge repair system; TriClip, a tricuspid valve transcatheter edge-to-edge repair system; Epic, a surgical family of aortic valve and mitral valve replacement devices; Portico and Navitor transcatheter aortic heart valves; Regent and Masters Series mechanical heart valves; Amplatzer PFO occluders; Amplatzer Amulet occluder devices; and the Tendyne transcatheter mitral valve replacement system.

Continuous glucose and blood glucose monitoring systems under the FreeStyle brand such as the FreeStyle Libre system, including sensors, data management decision software, test strips, and accessories for people with diabetes.

Neuromodulation products, including spinal cord stimulators Proclaim Plus and Proclaim XR recharge-free implantable pulse generators (IPG) and rechargeable Eterna IPG, each with BurstDR stimulation, and Proclaim DRG IPG, a neurostimulation device designed for dorsal root ganglion therapy, for the treatment of chronic pain disorders; and the Infinity Deep Brain Stimulation System with directional lead technology for the treatment of movement disorders.

Patents, Trademarks, and Licenses

Abbott owns or has licenses under a substantial number of patents and patent applications. These, and various patents that expire during the period 2024 to 2044, in the aggregate, are believed to be of material importance in the operation of Abbott’s business.

Environmental Matters

Abbott has been identified as one of many potentially responsible parties in investigations and/or remediations at several locations in the United States, including Puerto Rico, under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund. Abbott is also engaged in remediation at several other sites, some of which are owned by Abbott, in cooperation with the Environmental Protection Agency or similar agencies.

Regulation

The development, manufacture, marketing, sale, promotion, and distribution of Abbott’s products are subject to comprehensive government regulation by the U.S. Food and Drug Administration (FDA) and similar international regulatory agencies.

In addition, Abbott’s clinical laboratories and associated testing services are subject to comprehensive government regulation, including registration, certification, and licensure, by federal, state, and local agencies, such as the Centers for Medicare & Medicaid Services, the Drug Enforcement Administration, the Substance Abuse and Mental Health Services Administration, and their respective foreign counterparts.

Research and Development

For the year ended December 31, 2023, the company’s research and development expenses were $2.7 billion.

History

Abbott Laboratories was founded in 1888. The company was incorporated in 1900 as an Illinois corporation.

Country
Founded:
1888
IPO Date:
01/02/1968
ISIN Number:
I_US0028241000

Contact Details

Address:
100 Abbott Park Road, Abbott Park, North Chicago, Illinois, 60064-6400, United States
Phone Number
224 667 6100

Key Executives

CEO:
Ford, Robert
CFO
Boudreau, Philip
COO:
Data Unavailable